← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections
elbasvir and grazoprevir
J05AP54
Forms & Strengths
- Tablets: elbasvir 50mg and grazoprevir 100mg
- Fixed-dose combination
Adult Dosing
- One tablet orally once daily with or without food
- Recommended treatment duration: 12 weeks
- Dose adjustment for renal impairment or hepatic impairment may be required
Pediatric Dosing
- Not established for patients under 18 years of age
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection
- Treatment of HCV genotype 1a or 1b in patients with or without cirrhosis
- Used in combination with ribavirin in certain patient populations
Mechanism of Action
- Elbasvir: HCV NS5A inhibitor
- Grazoprevir: HCV NS3/4A protease inhibitor
- Inhibit viral replication by targeting different proteins
Contraindications
- Hypersensitivity to elbasvir or grazoprevir
- Co-administration with certain medications (e.g., alfuzosin, carbamazepine, phenytoin)
- Presence of decompensated liver disease
Adverse Reactions
- Fatigue
- Headache
- Nausea
- Diarrhea
- Elevations in alanine transaminase (ALT) and aspartate transaminase (AST)
Drug Interactions
- Strong CYP3A inhibitors (e.g., clarithromycin, itraconazole, ketoconazole)
- Strong CYP3A inducers (e.g., carbamazepine, phenytoin, rifampin)
- BCRP inhibitors (e.g., cyclosporine)
- Drugs highly dependent on CYP3A for clearance
Curated Content: Needs Vetting Before Put to Clinical Use